D202 Rescue Medication Use and Inhalation Patterns During Asthma Exacerbations Recorded by Digihaler

Pleasants, Roy A.; Safioti, Guilherme; Reich, Michael; Granovsky, Lena; Itzahary, Or; Hadar, Yonathan; Li, T.; Hill, T.; DePietro, Michael; Chrystyn, Henry

doi:10.1016/j.anai.2019.08.072

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inspiratory-capable digital inhalers add a physiological measure to the drug usage data around exacerbations. Similar to peak expiratory flow, peak inspiratory flow (PIF) is responsive to bronchodilators [ 81 ] and decreases during exacerbations [ 74 , 76 , 82 ]. Air trapping and airflow obstruction are important mechanisms for reducing PIF [ 83 , 84 ].…”

Section: Methodsmentioning

confidence: 99%

“…In hospitalized patients with COPD or asthma, Chrystyn and colleagues found that PIF measured with a portable inspiratory flow meter was low upon admission (often < 30 L/min), and increased over several days [ 83 ]. In a study of 360 adults with asthma using the Digihaler ® , 64 of whom experienced an exacerbation, PIF began decreasing about 5 days prior to the exacerbation, then returned to baseline over a similar interval [ 74 ]. A study of the ProAir Digihaler ® in 336 patients with COPD, of whom about one-third ( n = 98) reported an exacerbation, found that PIF had not returned to baseline by 14 days, similar to expiratory flow patterns reported post-exacerbation [ 85 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

et al. 2021

View full text Add to dashboard Cite

Impressive advances in inhalation therapy for patients with asthma and chronic obstructive pulmonary disease (COPD) have occurred in recent years. However, important gaps in care remain, particularly relating to poor adherence to inhaled therapies. Digital inhaler health platforms which incorporate digital inhalers to monitor time and date of dosing are an effective disease and medication management tool, promoting collaborative care between clinicians and patients, and providing more in-depth understanding of actual inhaler use. With advances in technology, nearly all inhalers can be digitalized with add-on or embedded sensors to record and transmit data quantitating inhaler actuations, and some have additional capabilities to evaluate inhaler technique. In addition to providing an objective and readily available measure of adherence, they allow patients to interact with the device directly or through their self-management smartphone application such as via alerts and recording of health status. Clinicians can access these data remotely and

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The Digihaler ® contains an integrated digital sensor encompassed in an electronic module (eModule) on the top portion of the inhaler that can record usage (date and time), inhalation data relevant to the inhalation technique (e.g., PIF and flow volume), and provide medication reminders [109,118]. The accuracy, benefits, and outcomes of such digital DPIs, such as the Digihaler ® , are beginning to emerge [110,119,120]. Other FDA-approved digital DPIs included add-on sensors rather than being fully integrated in the DPI device.…”

Section: Advancements In Dpi Device Technologiesmentioning

confidence: 99%

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development

et al. 2022

View full text Add to dashboard Cite

Dry powder inhalers (DPIs) are drug–device combination products where the complexity of the formulation, its interaction with the device, and input from users play important roles in the drug delivery. As the landscape of DPI products advances with new powder formulations and novel device designs, understanding how these advancements impact performance can aid in developing generics that are therapeutically equivalent to the reference listed drug (RLD) products. This review details the current understanding of the formulation and device related principles driving DPI performance, past and present research efforts to characterize these performance factors, and the implications that advances in formulation and device design may present for evaluating bioequivalence (BE) for generic development.

show abstract

Smart dry powder inhalers and intelligent adherence management

Häußermann¹,

Arendsen²,

Pritchard³

2022

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

D202 Rescue Medication Use and Inhalation Patterns During Asthma Exacerbations Recorded by Digihaler

Cited by 4 publications

References 0 publications

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development

Smart dry powder inhalers and intelligent adherence management

Contact Info

Product

Resources

About